Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Down 86.7% in January

Bioxytran, Inc. (OTCMKTS:BIXT) was the target of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 10,300 shares, a drop of 86.7% from the December 31st total of 77,600 shares. Based on an average daily volume of 153,100 shares, the short-interest ratio is presently 0.1 days.

Bioxytran Price Performance

Bioxytran stock opened at $0.09 on Wednesday. Bioxytran has a 12 month low of $0.06 and a 12 month high of $0.15. The stock has a fifty day simple moving average of $0.09 and a two-hundred day simple moving average of $0.10.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.